Silexion Therapeutics Corp
3.4400+0.01 (+0.29%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · SLXN · USD
Key Stats
Market Cap
10.76MP/E (TTM)
-Basic EPS (TTM)
-30.78Dividend Yield
0%Recent Filings
8-K
Nasdaq compliance restored
Silexion Therapeutics secured Nasdaq's confirmation on September 23, 2025, restoring compliance with the $2.5 million shareholders' equity rule and $1.00 minimum bid price after recent financings boosted equity by $10.3 million to $9.41 million pro forma. A 1-for-15 reverse share split on July 29, 2025, lifted the stock price above $1.00. Compliance holds, but a one-year panel monitor until September 23, 2026, means any equity slip triggers delisting without cure.
8-K
Silexion affirms Nasdaq equity compliance
Silexion Therapeutics issued 450,000 ordinary shares to its sponsor on September 15, 2025, converting $1.8 million of a $3.4 million promissory note at $4.00 per share, trimming the balance to $1.6 million. This move, alongside a $6.0 million public offering, warrant exercises netting $1.8 million, and an inducement transaction adding $1.5 million, boosted shareholders' equity from a $0.7 million deficiency on July 31 to $9.41 million pro forma. Compliance secured. Nasdaq awaits confirmation.
8-K
Silexion prices $6M offering
Silexion Therapeutics priced a $6.0 million public offering on September 11, 2025, selling 1,392,250 ordinary shares and 107,750 pre-funded warrants alongside 1,500,000 Series A and Series B warrants, each exercisable at $4.00 per share. The deal closed September 12, netting $5.2 million after fees to advance pre-clinical and clinical studies for KRAS-driven cancers, plus general purposes. Warrants cap ownership at 4.99% or 9.99% to curb dilution. Funds fuel oncology pipeline, but regulatory hurdles loom.
8-K
Positive SIL204 metastatic data
Silexion Therapeutics unveiled positive preclinical data on September 11, 2025, showing its RNAi therapy SIL204 reaches key pancreatic cancer metastatic sites—liver, peritoneum, and lung—via subcutaneous injection, achieving statistically significant tumor burden reductions at human-equivalent doses in KRAS G12D models. This validates the systemic arm of their dual-route strategy, complementing prior intratumoral efficacy for tackling both primary and disseminated disease, where metastases drive over 80% of fatalities. Expanded studies across KRAS mutations are underway. Silexion targets Phase 2/3 trial start in H1 2026 post Q4 2025 and Q1 2026 submissions, though regulatory hurdles loom.
8-K
CRO selected for SIL204 trials
Silexion Therapeutics selected AMS as its contract research organization on September 4, 2025, to manage upcoming Phase 2/3 trials for SIL204, its RNAi therapy targeting KRAS-driven cancers. AMS's 28 years of oncology expertise will support regulatory submissions to Israel in Q4 2025 and the EU in Q1 2026, with trials starting in H1 2026. This builds on SIL204's preclinical 97% inhibition in pancreatic cancer models. Forward-looking plans hinge on regulatory approvals.
BLRX
BioLineRx Ltd.
3.50-0.18
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
LADX
LadRx Corporation
0.80+0.00
LXRX
Lexicon Pharmaceuticals, Inc.
1.33-0.04
SION
Sionna Therapeutics, Inc.
37.52-1.93
SLN
Silence Therapeutics Plc - Amer
7.23-0.08
SLRX
Salarius Pharmaceuticals, Inc.
3.85+0.13
SNSE
Sensei Biotherapeutics, Inc.
9.38-0.24
TNGX
Tango Therapeutics, Inc.
7.83+0.04
XLO
Xilio Therapeutics, Inc.
0.81-0.01